COVID-19 (Coronavirus)


The COVID-19 pandemic is rapidly evolving. Molina would like to share resources and updates with our provider partners.

As the COVID-19 public health concern grows, Molina Healthcare would like to share resources with our provider partners. Our corporate Chief Medical Office (CMO) is working closely with our health plan CMOs across the country to ensure that we are prepared to assist our members and providers. We will keep this page updated with new resources as they become available.




ICD-10 Description
B97.29 Other coronavirus as the cause of diseases classified elsewhere
Z03.818 Encounter for observation for suspected exposure to other biological agents - ruled out
Z20.828 Contact with and (suspected) exposure to other viral communicable diseases
U07.1 COVID-19 Confirmed Cases, virus identified. Assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing.
U07.2 COVID-19 Suspected/Probable cases, virus not identified. Assigned to a clinical or epidemiological diagnosis of COVID-19 where laboratory confirmation is inconclusive or not available.
CPT HPCS Description
U0001 This code is used specifically for CDC testing laboratories
U0002 This code is used for non–CDC testing laboratories
87635 This code is used for non-CDC testing laboratories (effective 3/13/2020). Provider can choose to use U0002 or 87635
86328 Effective 04/10/20
86328 (Immunoassay for infectious agent antibody[ies], qualitative or semiquantitative, single step method [eg, reagent strip]; severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [Coronavirus disease (COVID-19)]
86769 Effective 04/10/20
86769 (Antibody; severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [Coronavirus disease (COVID-19)]
U0003 Effective 04/14/20
U0003 (Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [Coronavirus disease (COVID-19)], amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R)
U0004 Effective 04/14/20
U0004 (2019-nCoV Coronavirus, SARS-CoV-2/2019-nCov [COVID-19], any technique, multiple types or subtypes [includes all targets], non-CDC, making use of high throughput technologies as described by CMS-2020-01-R)

  • Molina will waive co-pays and cost share for any COVID-19 related diagnostic laboratory testing, office visits, urgent care visits and ED visits. Molina will cover the test kit for patients who meet CDC guidelines for testing, which can be done in any authorized location (excluding LabCorp or Quest sites). No prior authorization is needed for this testing.
  • Visits for any other symptoms or diagnoses will continue to have co-pays and cost share. This includes other laboratory testing (besides COVID-19 testing), x-rays or add-on testing.

Molina Healthcare Extends COVID-19 Testing and Treatment Cost Waivers